Medicare's First Negotiated Drug Price for Januvia Takes Effect, Impacting Diabetes Treatment Costs
As of January 1, 2026, the first directly negotiated Medicare price for the diabetes drug Januvia has taken effect. This marks a significant milestone under the Medicare Drug Price Negotiation Program, established by the Inflation Reduction Act. The Centers for Medicare & Medicaid Services (CMS) announced on August 15, 2024, that negotiations concluded with agreements on prices for ten selected high-spending Part D drugs, including Januvia. Merck Sharp Dohme's Januvia was among the initial drugs chosen for negotiation on August 29, 2023. In 2023, approximately 850,000 Medicare beneficiaries used Januvia, with Medicare's Part D program spending over $4 billion on the drug. While the exact negotiated price for Januvia has not been publicly disclosed, CMS mandates that participating manufacturers make these negotiated prices available to pharmacies and other dispensing entities. The negotiated price sets the maximum amount plans can pay pharmacies, plus dispensing fees, though individual beneficiary costs wil...